Combining smoking-cessation support with low-dose CT lung screening
Official title: Integrating Smoking Cessation With Low-dose CT-screening for Lung Cancer - a Randomized Study
Run by Oulu University Hospital · NCT07331519 · Data updated 2026-11-12
This project tries to see if combining low-dose CT scans with smoking-cessation support (a smartphone app or written materials) helps people aged 50–74 who still smoke quit and find lung cancer earlier.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 74 Years |
| Sex | All |
| Enrollment | 1200 (estimated) |
| Sponsor | Oulu University Hospital Academic / other |
| Locations | 5 sites (Helsinki and 4 other locations) |
| Status | Recruiting |
| Started | February 2, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | August 31, 2036 |
| Registry record updated | February 6, 2026 |
| Trial ID | NCT07331519 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are current smokers aged 50–74 with a substantial long-term smoking history who can use a smartphone and are willing to attend study visits at a participating hospital.
✕Probably not a fit
People with a prior diagnosis of melanoma, lung, renal, or breast cancer, a chest CT within the past year, no smartphone access, or major psychiatric/substance-use issues that limit participation are unlikely to benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, randomized study that assigns current heavy smokers aged 50–74 to one of three groups: low-dose CT (LDCT) plus a smartphone smoking-cessation app, LDCT plus written cessation materials, or the smartphone app without LDCT. The trial compares quit rates between the cessation methods and examines whether LDCT changes the stage distribution and lung-cancer-specific survival. Participants must be current smokers with defined pack-year histories and have smartphone access. The study is conducted at multiple university hospitals in Finland with follow-up for lung cancer outcomes and survival.
Why it matters
Potential benefit: If successful, the approach could increase smoking-cessation rates and detect lung cancers at earlier stages, potentially improving lung-cancer-specific survival.
How similar studies have gone: LDCT screening has been shown to reduce lung-cancer mortality and smoking-cessation programs improve outcomes, but combining LDCT with smartphone-based cessation support is less well-studied.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Able to provide written informed consent 2. Age between 50-74 3. Smoked ≥ 15 cigarettes/day for ≥ 25 years or smoked ≥ 10 cigarettes/day for ≥ 30 years and are active smokers (smoking during the last two weeks) 4. Access to a smartphone (iPhone or Android) Exclusion Criteria: 1. Current or past melanoma, lung, renal or breast cancer 2. A chest CT examination less than one year before inclusion 3. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial 4. No access to a smartphone (iPhone or Android) 5. Participant is unwilling or unable to comply with treatment and trial instructions 6. Any condition that study investigators consider an impediment to safe trial participation
Where it's running
-
Oulu University Hospital
Oulu, Finland Recruiting -
Helsinki University Hospital
Helsinki, Finland Not yet recruiting -
Tampere University Hospital
Tampere, Finland Not yet recruiting -
Turku University Hospital
Turku, Finland Not yet recruiting -
Vaasa Central Hospital
Vaasa, Finland Not yet recruiting
Study contacts
- Study coordinator: Jussi P Koivunen, MD, PhD
- Email: jussi.koivunen@pohde.fi
- Phone: +358504182666
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Quitting Matters: a smoking quit program for people living with HIV
This 6-month program will test whether a tailored smartphone app plus nicotine patches and gum helps people living with HIV quit smoking better than a standard quit app.
-
Smoky Futures: Danish Adolescent Nicotine Use over Time
This observational cohort follows Danish youths ages 15–25 to see how cigarette, e-cigarette, and other nicotine use begin, change, and affect health and education over several years.
-
Nicotine Orodispersible Tablet to Relieve Cravings in Smokers
A nicotine mint orodispersible tablet is tested vs placebo to see if it quickly eases the urge to smoke in adult cigarette smokers.
-
Optimizing when weekly chatbot reminders go out to people using a chatbot for quitting smoking
This study tests whether sending weekly reminders at different times helps people stay engaged with a chatbot smoking-cessation service.
-
NMDA and Sigma-1 combination therapy for smoking cessation with AXS-05
This phase 3 trial tests whether AXS-05 can help adults quit smoking better than placebo or bupropion.
-
AI-assisted interactive case-based training to improve smoking cessation counseling by medical interns
This study tests whether AI-powered interactive case-based training helps medical interns provide better smoking cessation counseling.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.